StockData
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. (VVOS) stock

VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.08−0.00 (-4.64%)

Close on Nov 18, 2026Market cap $1.53MP/E –Yield –

Vivos Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vivos Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$22.56M. For fiscal 2025 it was -$19.89M. The highest annual figure on record is -$10.58M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.89M–
FY2024Dec 31, 2024-$11.17M–
FY2023Dec 31, 2023-$17.30M–
FY2022Dec 31, 2022-$25.03M–
FY2021Dec 31, 2021-$20.38M–
FY2020Dec 31, 2020-$12.04M–
FY2019Dec 31, 2019-$10.58M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.83M–
Q1 FY2026Mar 31, 2026-$6.62M–
Q4 FY2025Dec 31, 2025-$6.38M–
Q3 FY2025Sep 30, 2025-$4.73M–
Q2 FY2025Jun 30, 2025-$4.87M–
Q1 FY2025Mar 31, 2025-$3.92M–
Q4 FY2024Dec 31, 2024-$2.81M–
Q3 FY2024Sep 30, 2024-$2.65M–
Q2 FY2024Jun 30, 2024-$1.94M–
Q1 FY2024Mar 31, 2024-$3.79M–
Q4 FY2023Dec 31, 2023-$4.13M–
Q3 FY2023Sep 30, 2023-$3.64M–
Q2 FY2023Jun 30, 2023-$4.52M–
Q1 FY2023Mar 31, 2023-$5.01M–
Q4 FY2022Dec 31, 2022-$6.06M–
Q3 FY2022Sep 30, 2022-$5.41M–
Q2 FY2022Jun 30, 2022-$6.96M–
Q1 FY2022Mar 31, 2022-$6.64M–
Q4 FY2021Dec 31, 2021-$7.41M–
Q3 FY2021Sep 30, 2021-$5.50M–
Q2 FY2021Jun 30, 2021-$4.06M–
Q1 FY2021Mar 31, 2021-$3.41M–
Q4 FY2020Dec 31, 2020-$6.25M–
Q3 FY2020Sep 30, 2020-$1.82M–
Q2 FY2020Jun 30, 2020-$1.42M–
Q1 FY2020Mar 31, 2020-$2.56M–

More Vivos Therapeutics figures

See a number that looks wrong?